Evidence map›Paper›PMID 40459726›Full record

ReviewCurrent oncology reports2025

Merkel Cell Carcinoma: Current Treatment Landscape and Emerging Therapeutic Targets.

Kelly Pan, A Maria Vromans, Liang Cheng, Jane M Grant-Kels, Steven C Katz, Matthew J Hadfield

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kelly PanDepartment of Internal Medicine, Brown University Health, Providence, RI, USA.
A Maria VromansDepartment of Internal Medicine, Brown University Health, Providence, RI, USA.
Liang ChengDepartment of Pathology and Laboratory Medicine, Department of Surgery (Urology), Brown University Warren Alpert Medical School, Legorreta Cancer Center at Brown University, Brown University Health, Providence, RI, USA.
Jane M Grant-KelsUniversity of Connecticut Health Center, Farmington, CT, USA.
Steven C KatzDepartment of Surgery, Brown University Health, Providence, RI, USA.
Matthew J HadfieldBrown University/Legorreta Cancer Center, Providence, RI, USA. matthew_hadfield@brown.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewMerkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine carcinoma that is primarily driven by Merkel cell polyomavirus (MCPyV) and ultraviolet radiation. Due to its rarity and innocuous appearance on clinical exam, MCC diagnosis is often delayed and therefore diagnosed at advanced stages. Overall survival outcomes are poor and notably worse than melanoma, with an estimated five-year survival ranging from 35 to 60% for stage I or II disease to < 15% for metastatic disease. Our review examines the diagnostic workup, prognostic markers, and current and emerging treatments of MCC. RECENT

findingsFor local disease in which surgical resection is feasible, tumor removal with potential adjuvant radiation therapy is the primary treatment modality. Immunotherapy with PD-1 / PD-L1 inhibitors is now standard for advanced disease where complete resection is not feasible. Additionally, there are many ongoing clinical trials examining novel immune checkpoint inhibitors, immunomodulators, targeted therapies, cellular therapies, vaccines, and oncolytic virus therapies with the goal of improving outcomes for patients with advanced disease or those who experience recurrence after first-line immunotherapy. MCC is an aggressive disease with a rapidly evolving treatment landscape, and emerging therapies hold the potential to improve prognosis in advanced disease.

Indexed as

Carcinoma, Merkel CellSkin NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyMolecular Targeted TherapyPrognosisImmune Checkpoint InhibitorsCheckpoint inhibitorImmunotherapyMerkel cell carcinomaMerkel cell polyomavirus (MCPyV)PD-1PD-L1

Identifiers

PMID40459726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.